Victoria L Chiou
Overview
Explore the profile of Victoria L Chiou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
939
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cabrera C, Fernandez-Llaneza D, Ghazoui Z, DAbrantes S, Esparza-Franco M, Sopp C, et al.
Contemp Clin Trials
. 2024 Mar;
140:107496.
PMID: 38467274
Background: To develop medicines that are safe and efficacious to all patients, clinical trials must enroll appropriate target populations, but imbalances related to race, ethnicity and sex have been reported....
2.
Lampert E, Hays J, Kohn E, Annunziata C, Minasian L, Yu M, et al.
Oncotarget
. 2019 May;
10(30):2855-2868.
PMID: 31080557
To investigate maximum tolerated dose (MTD), activity and predictive biomarkers of olaparib with carboplatin in wild-type (wt) high grade serous ovarian carcinoma (HGSOC) patients. A 3+3 dose escalation study examined...
3.
Lee J, Hays J, Chiou V, Annunziata C, Swisher E, Harrell M, et al.
Oncotarget
. 2017 Nov;
8(45):79175-79187.
PMID: 29108297
Purpose: To investigate the safety, activity, and potential biomarkers of response to olaparib and carboplatin combination in sporadic triple negative breast cancer (TNBC). EXPERIMENTAL DESIGN: Metastatic or recurrent TNBC patients...
4.
Lee J, Peer C, Yu M, Amable L, Gordon N, Annunziata C, et al.
Clin Cancer Res
. 2016 Sep;
23(6):1397-1406.
PMID: 27663600
Our preclinical studies showed that the PARP inhibitor, olaparib, prior to carboplatin attenuated carboplatin cytotoxicity. We evaluated sequence-specific pharmacokinetic and pharmacodynamic effects, safety, and activity of the combination. Eligible patients...
5.
6.
7.
Burotto M, Chiou V, Lee J, Kohn E
Cancer
. 2014 Jun;
120(22):3446-56.
PMID: 24948110
The mitogen-activated protein kinase/extracellular signal-regulated (MAPK/ERK) pathway is activated by upstream genomic events and/or activation of multiple signaling events in which information coalesces at this important nodal pathway point. This...
8.
Rice A, Chiou V, Zuckoff S, Shapiro S
Brain Res
. 2010 Oct;
1368:290-8.
PMID: 20971088
Excessive hyperbilirubinemia in human neonates can cause permanent dysfunction of the auditory system, as assessed with brainstem auditory evoked potentials (BAEPs). Jaundiced Gunn rat pups (jjs) exhibit similar BAEP abnormalities...